



The Medicines Patent Pool Foundation Governance Board Meeting Chairman's Summary

November 2020



The Governance Board of the Medicines Patent Pool (MPP) thanks the Expert Advisory Group (EAG) and members of the Scientific Advisory Panel for their report assessing the final results of negotiations between MPP and ViiV on a licence agreement for dolutegravir in four upper-middle-income countries. The Board has reviewed the EAG report and the proposed Licence Agreement between MPP and ViiV. The Board agrees with the EAG's assessment that the proposed collaboration is consistent with the MPP's mandate as defined in its Statutes. And while the Board shares the concerns expressed by the EAG in relation to the proposed agreement's departure from MPP's practice of full transparency, it agrees with the EAG that the proposed agreement represents an improvement over the status quo.

Therefore, the Board requests the Executive Director to finalise and sign the necessary documents with ViiV to formalize the collaboration. The Board further reiterates MPP's continued commitment to transparency, and views this decision as an exceptional one that does not diminish this commitment.